Sun Pharma share price declines as it revises bid to buy balance Taro stake

Sun Pharmaceutical Industries share price, having gained 56% in the last six months, declined 1.91% in intraday trades on Tuesday. Sun Pharma remains focused on its plan to acquire 100% ownership in its US subsidiary Taro Pharmaceutical Industries.

Sun Pharma, after having announced its strategic plan in May 2023 to acquire 100% ownership of Taro now has increased its bid to purchase the outstanding shares of Taro Pharma. The revised offer stands at $43 per share in cash, an increase from the previous offer of $38 per share.

Sun Pharma already owns 78.5% of Taro and has been attempting to complete the buyout of the remaining shares for some time. After the acquisition, Sun Pharma is expected to benefit from integration and cost synergies in the manufacturing areas and can utilise Taro’s cash for Sun Pharma’s merger and acquisitions, said analysts.

Also Read- Mankind Pharma stock drops nearly 5% on large block deals

Taro has assets of $1.3 billion, with cash and short-term bank deposits totalling $274 million. Taro, which does most of its business in the United States and Canada, reported $573 million during its fiscal year 2023.

As progress on Taro share buyback will remain watched for, the prospects for Sun Pharma earnings are being led by the ramp-up of its specialty portfolio.

Analysts at Sharekhan expect Sun Pharma’s global specialty sales to surpass $1 billion in FY2024.

Sun Pharma has a healthy specialty portfolio of six drugs. US formulation sales at $430 million during Q2 grew 4.2% over the same period last year. Sun’s Global specialty sales at $240 million, grew 19.3% over Q2 last year. Sun Pharma is planning to expand its specialty portfolio in other emerging markets.

Analysts at Sharekhan, factoring in a new product launch, expect Sun to take the global specialty portfolio to inch up to $280 million from $240 million per quarter.

Also Read-Dr Reddy's share price gains 2.96% as concerns around its FTO-3 facility ease

Sun Pharma continues to report decent earnings growth on account of strong growth in the US, emerging markets, and Rest of the world markets (RoW).

To be sure the regulatory clearance of Halol and Mohali plants from the USFDA also remains crucial. 

 However, analysts at Sharekhan expect Sun Pharma to post healthy sales and earnings CAGR (compound annual growth rate) of 12% and 17%, respectively, over FY2024-FY2026.

Disclaimer: The views and recommendations made above are those of individual analysts or broking companies, and not of Mint. We advise investors to check with certified experts before taking any investment decisions